Vascular Dementia

1. Clinical Overview

Summary

Vascular Dementia (VaD) is the second most common form of dementia after Alzheimer's disease, accounting for 15-20% of all dementia cases. It results from cerebrovascular disease that reduces blood flow to the brain, causing ischaemic or haemorrhagic injury to neural tissue. [1,2] Unlike Alzheimer's disease, VaD classically presents with a stepwise deterioration pattern and prominent executive dysfunction (impaired planning, slowed processing speed) that often precedes memory loss. The condition encompasses a spectrum of presentations from multi-infarct dementia (following large vessel strokes) to subcortical ischaemic vascular dementia (small vessel disease). [3]

The pathophysiology involves multiple mechanisms: macrovascular disease causing cortical infarcts, microvascular disease (arteriolosclerosis) affecting white matter and deep grey structures, and strategically placed single infarcts in critical regions such as the thalamus or angular gyrus. [4] The term Vascular Cognitive Impairment (VCI) is increasingly used to describe the full spectrum from mild cognitive impairment to frank dementia caused by cerebrovascular disease. [5]

Management is fundamentally different from Alzheimer's disease. The cornerstone of treatment is aggressive vascular risk factor modification to prevent further cerebrovascular events and halt progression. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine have limited evidence for efficacy in pure vascular dementia and are not recommended by NICE guidelines, unlike their established role in Alzheimer's disease. [6] The prognosis is generally worse than Alzheimer's disease due to the high burden of cardiovascular comorbidity and increased mortality risk. [7]

Key Facts

• Prevalence: 15-20% of all dementia cases; second most common after Alzheimer's disease [1]
• Mixed Dementia: Alzheimer's + vascular pathology coexist in over 30% of elderly patients with dementia [2]
• Pathological Spectrum:
  • Multi-infarct dementia (large vessel, cortical)
  • Subcortical ischaemic vascular dementia (small vessel disease, Binswanger's disease)
  • Strategic infarct dementia (single critical location)
  • Hypoperfusion/watershed infarcts
  • Cerebral haemorrhage (intracerebral, subarachnoid)
• Clinical Pattern: Stepwise decline (in multi-infarct) vs gradual decline (in small vessel disease)
• Cognitive Profile: Executive dysfunction > memory impairment (reversal of Alzheimer's pattern)
• Neurological Features: Gait disturbance, pseudobulbar palsy, focal neurological signs, early urinary symptoms
• Imaging: MRI showing white matter hyperintensities (leukoaraiosis), lacunar infarcts, cortical infarcts, microbleeds
• Treatment Paradigm: Vascular risk factor control is the ONLY evidence-based intervention to prevent progression [6]

Clinical Pearls

The "Stepwise" Decline: The classic textbook description is a patient who remains cognitively stable, experiences a vascular event (stroke or TIA), drops a functional level, stabilises, then drops again after subsequent events. However, subcortical small vessel disease often presents with gradual, insidious decline mimicking Alzheimer's disease, making clinical distinction challenging. [3]

Executive Dysfunction First: Unlike Alzheimer's disease where memory loss is the presenting feature, VaD typically presents with impaired executive function—difficulty with planning, organisation, problem-solving, and slowed processing speed (bradyphrenia). Patients struggle with complex tasks, multi-step activities, and abstract reasoning before significant memory impairment. [8]

Gait as a Diagnostic Clue: Alzheimer's patients typically maintain normal gait until late stages. In contrast, VaD patients often develop early gait disturbance: small-stepped ("marche à petits pas"), shuffling, broad-based, or apraxic gait. This reflects disruption of frontal-subcortical motor circuits. [9]

Emotional Incontinence (Pseudobulbar Affect): Pathological laughing or crying—emotional responses that are exaggerated, sudden, and incongruent with the stimulus—results from bilateral corticobulbar tract damage. Patients cry when discussing mundane topics or laugh inappropriately, causing significant social embarrassment. [10]

Executive vs Memory Testing: If a patient fails the clock drawing test (executive/visuospatial) but recalls three words at 5 minutes (memory intact), think vascular or Lewy body dementia rather than Alzheimer's disease. The MoCA is superior to MMSE for detecting executive dysfunction. [11]

CADASIL: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy is a genetic form of VaD caused by NOTCH3 mutations. Consider in patients with early-onset (less than 65 years) vascular dementia, recurrent strokes, migraine with aura, and family history. Diagnosis is by genetic testing or skin biopsy showing NOTCH3 deposits. [12]

---

2. Epidemiology

Incidence and Prevalence

• Prevalence: Vascular dementia affects approximately 1.5% of the population over 65 years, rising to 5-10% over 80 years [1]
• Incidence: 6-12 cases per 1,000 person-years in those aged over 70 [2]
• Post-stroke dementia: 20-30% of stroke survivors develop dementia within 3 months of the event [13]
• Geographic Variation: Higher prevalence in Asian populations (particularly Japan, China) compared to Western populations, likely reflecting differences in stroke incidence and vascular risk factors [1]

Demographics

Risk Factors

Cardiovascular Risk Factors (Modifiable)

The risk factors for vascular dementia are essentially identical to those for stroke:

Non-Modifiable Risk Factors

• Age: Most powerful risk factor
• Genetics: CADASIL, APOE ε4 allele (modest effect compared to Alzheimer's)
• Male sex
• Family history of stroke or dementia

Novel Risk Factors (Emerging Evidence)

• Chronic kidney disease: Associated with cerebral small vessel disease [16]
• Obstructive sleep apnoea: Intermittent hypoxia and cerebrovascular damage
• Inflammatory markers: Elevated CRP, IL-6 associated with increased risk [17]
• Homocysteine: Elevated levels associated with increased risk

---

3. Aetiology and Pathophysiology

Mechanisms of Cerebrovascular Injury

Vascular dementia results from multiple pathophysiological mechanisms that cause chronic or acute brain injury through vascular compromise:

1. Multi-Infarct Dementia (Large Vessel Disease)

• Mechanism: Multiple cortical and/or subcortical infarcts due to large vessel atherosclerosis, embolism (cardiac or artery-to-artery), or vessel occlusion
• Critical Volume Threshold: Cognitive impairment correlates with total volume of infarcted tissue. Threshold typically 50-100 mL of cumulative infarct volume [3]
• Location Matters: Dominant hemisphere lesions (language areas), bilateral lesions, and strategic locations produce disproportionate cognitive impact
• Presentation: Often stepwise decline; acute deficits following strokes with partial recovery but residual cognitive impairment

2. Subcortical Ischaemic Vascular Dementia (Small Vessel Disease)

Also known as Binswanger's Disease or Subcortical Arteriosclerotic Encephalopathy.

• Mechanism: Arteriolosclerosis (lipohyalinosis, fibrinoid necrosis) of small penetrating arteries supplying white matter and basal ganglia. Chronic hypoperfusion causes diffuse white matter ischaemia and lacunar infarcts (small cavitary infarcts less than 15mm). [4]
• Affected Structures:
  • Periventricular and deep white matter
  • Basal ganglia (caudate, putamen, globus pallidus)
  • Thalamus
  • Pons
• Circuit Disruption: Ischaemia disconnects frontal-subcortical circuits (dorsolateral prefrontal, anterior cingulate, orbitofrontal circuits), producing characteristic executive dysfunction, psychomotor slowing, apathy, and gait disturbance. [9]
• Pathology: White matter shows pallor, myelin loss, gliosis, enlarged perivascular spaces (état criblé)
• Presentation: Insidious, gradual decline (not stepwise); often misdiagnosed as Alzheimer's disease

3. Strategic Infarct Dementia

A single infarct in a critical location can cause dementia:

4. Hypoperfusion (Watershed Infarcts)

• Mechanism: Global hypoperfusion events (cardiac arrest, severe hypotension, anaemia) cause ischaemia in watershed zones between major arterial territories
• Affected Areas: Bilateral parieto-occipital regions, subcortical white matter
• Presentation: Can present acutely or with delayed cognitive decline

5. Cerebral Haemorrhage

• Intracerebral haemorrhage: Hypertensive haemorrhage, cerebral amyloid angiopathy (lobar haemorrhages)
• Subarachnoid haemorrhage: Can cause delayed cognitive impairment
• Microbleeds: Detected on susceptibility-weighted imaging (SWI); marker of small vessel disease

Molecular and Cellular Pathophysiology

Exam Detail: #### Endothelial Dysfunction

Chronic vascular risk factors (hypertension, diabetes, hyperlipidaemia) cause endothelial dysfunction:

• Reduced nitric oxide (NO) bioavailability: Impaired vasodilation, increased vascular tone
• Increased oxidative stress: Reactive oxygen species (ROS) damage endothelium
• Pro-inflammatory state: Upregulation of adhesion molecules (ICAM-1, VCAM-1), cytokine release
• Blood-brain barrier (BBB) breakdown: Increased permeability allows extravasation of proteins, oedema

Cerebral Autoregulation Impairment

• Normal cerebral autoregulation maintains constant cerebral blood flow (CBF) across mean arterial pressure (MAP) range 60-150 mmHg
• Chronic hypertension shifts autoregulation curve rightward, making brain vulnerable to hypoperfusion at "normal" blood pressures
• Small vessel disease impairs autoregulation, causing pressure-passive flow and white matter hypoperfusion [14]

White Matter Vulnerability

• Watershed location: Periventricular white matter is end-zone of vascular supply (long penetrating arteries from cortex vs short arteries from ventricle)
• Oligodendrocyte vulnerability: Oligodendrocytes (myelin-producing cells) are highly metabolically active and vulnerable to ischaemia
• Chronic hypoperfusion causes demyelination, axonal loss, gliosis → leukoaraiosis (white matter hyperintensities on MRI) [4]

Inflammation and Neurodegeneration

• Cerebrovascular injury triggers inflammatory cascade: microglial activation, astrocytosis, cytokine release (TNF-α, IL-1β, IL-6)
• Chronic inflammation contributes to ongoing neurodegeneration, BBB disruption, and impaired neuronal function [17]
• Neurovascular unit dysfunction: Interaction between neurons, glia, and vasculature is disrupted

Relationship with Alzheimer's Disease (Mixed Dementia)

• Coexistence is the rule: Autopsy studies show > 30% of elderly dementia patients have both Alzheimer's pathology (amyloid plaques, tau tangles) and significant cerebrovascular disease [2]
• Synergistic interaction: Vascular pathology lowers the threshold for Alzheimer's pathology to cause clinical dementia
• Clinical implication: Pure vascular dementia is relatively uncommon; most cases are "mixed" pathology

---

4. Clinical Presentation

Temporal Pattern of Decline

Cognitive Domain Profile

Unlike Alzheimer's disease (memory-predominant), vascular dementia shows executive-predominant pattern:

Executive Function Deficits (Hallmark)

• Planning and Organisation: Difficulty with multi-step tasks, meal preparation, financial management
• Problem-Solving: Impaired ability to generate solutions, flexible thinking
• Abstract Reasoning: Concrete thinking; difficulty with proverbs, similarities
• Set-Shifting: Perseveration; difficulty switching between tasks or mental sets
• Processing Speed: Bradyphrenia (slowed thinking); prolonged response latency

Attention and Concentration

• Reduced sustained attention
• Easily distracted
• Difficulty with divided attention tasks

Memory

• Retrieval Deficit (rather than encoding deficit): Patients benefit from cues and recognition testing (contrast to Alzheimer's where cues don't help because encoding failed)
• Free recall impaired but recognition relatively preserved
• Working memory impaired (frontal-subcortical circuits)

Language

• Generally preserved in early stages (unless stroke affects language areas)
• May have reduced verbal fluency (frontal dysfunction)
• Word-finding difficulties less prominent than in Alzheimer's

Visuospatial Function

• Constructional apraxia (clock drawing, copying figures)
• Difficulty with spatial navigation

Neurological Features

Vascular dementia commonly presents with neurological signs (unlike Alzheimer's):

Gait Disturbance (Early and Prominent)

• Subcortical gait (frontal gait, lower-body parkinsonism):
  • Small-stepped, shuffling gait ("marche à petits pas")
  • Broad-based, unsteady
  • Start hesitation, turning difficulty
  • Gait apraxia: Difficulty initiating gait despite normal leg strength ("magnetic feet")
  • Preserved arm swing (unlike Parkinson's disease)
• High fall risk: Postural instability, impaired balance
• Mechanism: Disruption of frontal-basal ganglia-thalamic motor circuits [9]

Upper Motor Neurone Signs

• Brisk deep tendon reflexes
• Extensor plantar responses (Babinski sign)
• Spastic hypertonia
• Focal weakness (residual from previous strokes)

Pseudobulbar Palsy

• Dysarthria: Spastic, strained-strangled voice
• Dysphagia: Difficulty swallowing; aspiration risk
• Emotional Incontinence (Pseudobulbar Affect): Pathological laughing/crying; sudden, exaggerated, incongruent emotional responses [10]
• Mechanism: Bilateral corticobulbar tract lesions from multiple lacunar infarcts or diffuse white matter disease

Urinary Symptoms (Early)

• Urge incontinence, frequency, nocturia
• Earlier than in Alzheimer's disease
• Mechanism: Frontal-subcortical bladder control disruption

Parkinsonism

• Bradykinesia, rigidity (predominantly lower body)
• Vascular parkinsonism: Symmetrical, lower-body predominant, poor response to levodopa
• Differentiate from Lewy body dementia (asymmetric, responds to levodopa) and Parkinson's disease dementia

Psychiatric and Behavioural Features

Subcortical vs Cortical Patterns

---

5. Diagnostic Criteria

NINDS-AIREN Criteria (1993)

The National Institute of Neurological Disorders and Stroke – Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria are the most widely used research criteria for probable and possible vascular dementia:

Probable Vascular Dementia

1. Dementia: Cognitive decline from previous higher level of function, documented by clinical examination and neuropsychological testing, causing impairment in activities of daily living
2. Cerebrovascular Disease: Clinical evidence (focal neurological signs) and/or neuroimaging evidence (CT/MRI) of cerebrovascular disease
3. Relationship between 1 and 2:
   • Onset of dementia within 3 months of stroke (for post-stroke dementia)
   • Abrupt deterioration or stepwise progression
   • Fluctuating course

Features Supporting Diagnosis

• Early gait disturbance
• History of unsteadiness, frequent unprovoked falls
• Early urinary frequency, urgency, incontinence
• Pseudobulbar palsy
• Personality and mood changes (depression, emotional incontinence)

Features Making Diagnosis Uncertain or Unlikely

• Early memory deficit with progressive worsening (suggests Alzheimer's)
• Absence of focal neurological signs (except cognitive)
• Absence of cerebrovascular lesions on CT/MRI

DSM-5 Criteria: Major or Mild Vascular Neurocognitive Disorder

1. Criteria for major or mild neurocognitive disorder are met
2. Clinical features consistent with vascular aetiology:
   • Onset temporally related to cerebrovascular event, OR
   • Evidence of cognitive decline in complex attention and frontal-executive function
3. Neuroimaging evidence of cerebrovascular disease
4. Symptoms not better explained by another disorder

Vascular Behavioural and Cognitive Disorders (VASCOG) Criteria (2014)

More recent criteria emphasising early executive dysfunction and incorporating modern neuroimaging:

• Vascular Cognitive Impairment (VCI): Broad term encompassing mild to severe impairment
• Vascular Mild Cognitive Impairment (VaMCI): Cognitive impairment not meeting dementia criteria
• Vascular Dementia: Frank dementia with vascular aetiology

Hachinski Ischaemic Score (Historical)

A clinical scoring system (now largely historical) to differentiate vascular dementia from Alzheimer's disease:

• Score ≥7: Vascular dementia likely
• Score ≤4: Alzheimer's disease likely
• Score 5-6: Mixed dementia

(Note: Largely superseded by modern neuroimaging but useful for historical perspective)

---

6. Clinical Examination

Cognitive Assessment

Screening Instruments

Key Examination Findings Suggesting VaD

• Executive tasks impaired: Clock drawing, verbal fluency, trails, set-shifting
• Memory relatively preserved: Recall improves with cues (retrieval deficit)
• Processing speed slowed: Prolonged latency to respond

Neurological Examination

Gait Assessment (Critical)

• Observe walking: stride length, speed, symmetry, arm swing, turning, tandem gait
• Subcortical gait: Short-stepped, shuffling, broad-based, hesitant start
• Gait apraxia: Feet appear "stuck to floor" despite normal leg power
• Postural stability testing (pull test)

Motor Examination

• Tone: Spasticity (UMN), rigidity (parkinsonism)
• Power: Focal weakness (previous stroke)
• Reflexes: Brisk (UMN); symmetry
• Plantar responses: Extensor (Babinski)

Cranial Nerves

• Pseudobulbar palsy:
  • Dysarthria (spastic, strained)
  • Brisk jaw jerk
  • Exaggerated gag reflex
  • Facial diplegia (bilateral UMN facial weakness)

Primitive Reflexes (Frontal Release Signs)

• Grasp reflex
• Palmomental reflex
• Snout/pout reflex
• (Present in advanced cases; not specific)

Cardiovascular Examination

• Blood pressure: Hypertension (seated and standing—check for orthostatic hypotension)
• Pulse: Irregularly irregular (atrial fibrillation)
• Carotid auscultation: Bruits (carotid stenosis)
• Cardiac auscultation: Murmurs (valvular disease, source of emboli)
• Peripheral pulses: Peripheral vascular disease

Functional Assessment

• Activities of Daily Living (ADL):
  • "Basic ADL: Bathing, dressing, toileting, eating, transferring"
  • "Instrumental ADL: Cooking, finances, medication management, transportation"
• Informant history: Essential; patients often lack insight into deficits

---

7. Investigations

Essential Investigations (All Patients)

"Dementia Screen" – Rule Out Reversible Causes

Neuroimaging (Essential for Diagnosis)

CT Brain (First-Line)

Adequate for:

• Excluding space-occupying lesion (tumour, subdural haematoma)
• Demonstrating large cortical/subcortical infarcts
• Showing gross atrophy, hydrocephalus

Limitations:

• Poor sensitivity for white matter changes
• Cannot detect microbleeds
• Inferior to MRI for small vessel disease

MRI Brain (Gold Standard)

Essential Sequences:

MRI Interpretation:

• Fazekas Scale (White Matter Hyperintensities):
  • "0: None or single punctate lesion"
  • "1: Multiple punctate lesions"
  • "2: Beginning confluent lesions"
  • "3: Large confluent lesions"
• High burden (Fazekas 2-3) strongly supports vascular cognitive impairment [4]

Characteristic MRI Pattern in Subcortical VaD:

• Extensive periventricular and deep white matter hyperintensities
• Multiple lacunar infarcts in basal ganglia, thalamus
• Relative preservation of cortex and hippocampus (contrast to Alzheimer's where hippocampal atrophy prominent)

Cardiovascular Investigations

Cerebrospinal Fluid (CSF) Analysis (Selective)

Not routine for vascular dementia; reserve for:

• Suspected inflammatory/autoimmune dementia
• Rapidly progressive dementia (CJD, autoimmune encephalitis)
• Suspected infection (neurosyphilis, HIV, chronic meningitis)

In research settings: CSF biomarkers (Aβ42, tau, phospho-tau) to assess for coexisting Alzheimer's pathology (mixed dementia)

Neuropsychological Testing (Specialist Referral)

Formal neuropsychological assessment by clinical psychologist if:

• Diagnostic uncertainty
• Quantify impairment across cognitive domains
• Differentiate from depression (pseudodementia)
• Medico-legal (capacity, disability assessment)

Domains Assessed:

• Executive function (Wisconsin Card Sorting Test, Stroop Test, Trail Making Test)
• Memory (recall vs recognition)
• Attention and processing speed
• Language
• Visuospatial function

---

8. Management

Management Principles

Vascular dementia management differs fundamentally from Alzheimer's disease:

1. Primary Goal: Prevent further cerebrovascular events through aggressive vascular risk factor control. This is the ONLY evidence-based strategy to halt progression. [6]
2. Cognitive Enhancers: Cholinesterase inhibitors and memantine are NOT recommended for pure vascular dementia (limited evidence of benefit). [6]
3. Exception: In mixed dementia (Alzheimer's + vascular), cognitive enhancers may be appropriate.
4. Multidisciplinary Approach: Geriatrician, neurologist, GP, OT, PT, speech therapy, mental health services, social services

Management Algorithm

    VASCULAR DEMENTIA DIAGNOSIS CONFIRMED
    (Clinical + Imaging Evidence of CVD)
                    ↓
┌──────────────────────────────────────────────────────┐
│  VASCULAR RISK FACTOR CONTROL (MAINSTAY)             │
│  ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━  │
│  • Blood Pressure: Target less than 140/90 mmHg               │
│  • Antiplatelet: Clopidogrel 75mg OD                 │
│    (or anticoagulation if AF)                        │
│  • Statin: Atorvastatin 80mg (secondary prevention)  │
│  • Diabetes Control: Target HbA1c less than 58 mmol/mol       │
│  • Smoking Cessation                                 │
│  • Lifestyle: Diet, exercise, alcohol moderation     │
└──────────────────────────────────────────────────────┘
                    ↓
┌──────────────────────────────────────────────────────┐
│  SYMPTOM MANAGEMENT                                  │
│  ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━  │
│  • Depression: SSRI (Sertraline, Citalopram)        │
│  • Agitation/BPSD: Non-drug first; avoid sedatives  │
│  • Gait/Falls: Physiotherapy, mobility aids         │
│  • Urinary Symptoms: Exclude UTI; anticholinergics  │
│    cautiously (worsen cognition)                     │
└──────────────────────────────────────────────────────┘
                    ↓
       ASSESS FOR MIXED DEMENTIA
       (Alzheimer's + Vascular Pathology)
       Evidence of prominent memory loss?
       Hippocampal atrophy on MRI?
              ↓                  ↓
           NO: Pure VaD      YES: Mixed Dementia
              ↓                  ↓
      Continue vascular     CONSIDER AChE Inhibitors
      prevention only       (Donepezil, Rivastigmine)
                           + Vascular prevention
                                  ↓
┌──────────────────────────────────────────────────────┐
│  SUPPORTIVE CARE (ALL PATIENTS)                      │
│  ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━  │
│  • Occupational Therapy: Home modifications, ADL    │
│  • Physiotherapy: Gait training, falls prevention   │
│  • Speech Therapy: Dysphagia assessment, SALT       │
│  • Driving Assessment: DVLA notification            │
│  • Legal: Advance directives, Power of Attorney     │
│    (while capacity retained), Mental Capacity Act   │
│  • Carer Support: Education, respite care, support  │
│    groups, Alzheimer's Society resources            │
└──────────────────────────────────────────────────────┘

---

1. Vascular Risk Factor Modification (Evidence-Based)

This is the cornerstone of vascular dementia management.

Hypertension Control

• Target: less than 140/90 mmHg (or less than 150/90 if > 80 years and frail) [14]
• Evidence: The HYVET-COG trial showed antihypertensive treatment in patients > 80 years reduced incidence of dementia by 14% (trend). Meta-analyses confirm benefit. [14]
• Agents: No specific agent superior; use ACE inhibitor/ARB, calcium channel blocker, or thiazide diuretic per standard guidelines
• Caution: Avoid aggressive lowering causing hypotension (may worsen cerebral perfusion, especially if impaired autoregulation)

Antiplatelet Therapy

• Clopidogrel 75mg once daily (first-line)
• Aspirin 75mg if clopidogrel contraindicated
• Dual antiplatelet (aspirin + clopidogrel) NOT recommended long-term (increased bleeding risk outweighs benefit)
• Evidence: Secondary stroke prevention; no RCT specifically for vascular dementia progression but extrapolated from stroke trials

Anticoagulation (if Atrial Fibrillation)

• Direct Oral Anticoagulants (DOACs) preferred: Apixaban, Rivaroxaban, Edoxaban, Dabigatran
• Warfarin if DOAC contraindicated (target INR 2-3)
• CHA2DS2-VASc score guides decision (most dementia patients score ≥2)
• Bleeding risk: Consider HAS-BLED score; manage reversible bleeding risks
• Evidence: AF anticoagulation reduces stroke risk by 64% and may reduce dementia incidence [15]

Lipid Management

• Atorvastatin 80mg (or high-intensity statin)
• Target: Not specific LDL target for dementia; use cardiovascular guidelines
• Evidence: Statins reduce recurrent stroke risk; indirect benefit on dementia progression [14]

Diabetes Control

• Target HbA1c: less than 58 mmol/mol (7.5%) in elderly; individualise to avoid hypoglycaemia
• Agents: Metformin first-line; SGLT2 inhibitors or GLP-1 agonists have cardiovascular benefits
• Avoid: Hypoglycaemia (worsens cognition acutely; patients may not recognise symptoms)

Lifestyle Modifications

---

2. Cognitive Enhancers (Limited Role)

Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)

• NICE Guidance (NG97, 2018): Do NOT offer for pure vascular dementia [6]
• Evidence: Multiple RCTs (GAL-INT-6, Donepezil VaD trials) showed small cognitive benefit on neuropsychological tests but NO functional benefit and increased adverse effects (nausea, diarrhoea, bradycardia)
• Exception: Mixed dementia (Alzheimer's + vascular). If prominent memory impairment and hippocampal atrophy suggest coexisting Alzheimer's pathology, consider trial of AChE inhibitor
  • "Donepezil: Start 5mg once daily, increase to 10mg after 4-6 weeks"
  • "Rivastigmine: Patch or oral"
  • "Galantamine: 8mg BD, increase to 12mg BD"
• Monitoring: Assess response after 3 months; discontinue if no benefit

Memantine

• NICE Guidance: Do NOT offer for vascular dementia [6]
• Evidence: No benefit demonstrated in RCTs for vascular dementia
• Exception: Mixed dementia with moderate-severe stage

---

3. Management of Behavioural and Psychological Symptoms of Dementia (BPSD)

Depression (50-60% prevalence)

• First-line: SSRIs (Sertraline 50-100mg, Citalopram 20mg)
• Avoid tricyclic antidepressants (anticholinergic, cardiac effects)
• Consider psychological therapy (CBT if mild)
• Duration: Continue 6-12 months after remission, then review

Apathy

• Distinguished from depression (no sadness, guilt, anhedonia)
• Non-pharmacological: Structured activities, occupational therapy
• Pharmacological: Limited options; some evidence for methylphenidate (off-label) in research settings

Agitation, Aggression, Psychosis

1. First-Line: Non-Pharmacological:
   • Identify and treat triggers: Pain, infection (UTI, pneumonia), constipation, environmental stressors
   • Behavioural strategies: Reassurance, distraction, calm environment
   • Carer education and support
2. Pharmacological (Last Resort):
   • Antipsychotics: Use ONLY if severe distress or risk to patient/others, after non-drug measures failed
   • Risks: Increased stroke risk (black box warning in dementia), sedation, falls, parkinsonism, increased mortality
   • If essential: Risperidone (lowest effective dose, 0.5-1mg) for shortest duration (review weekly, aim to withdraw after 6-12 weeks)
   • Avoid: Haloperidol (high extrapyramidal effects), quetiapine (less evidence)

---

4. Multidisciplinary Supportive Care

Occupational Therapy (OT)

• Home safety assessment and modifications (grab rails, remove trip hazards)
• Adaptive equipment (shower chair, raised toilet seat)
• ADL training and compensation strategies
• Cognitive aids (calendars, reminder systems)

Physiotherapy (PT)

• Gait and balance training
• Falls risk assessment and prevention strategies
• Mobility aids (walking stick, frame, wheelchair if appropriate)
• Exercise programmes to maintain strength and flexibility

Speech and Language Therapy (SALT)

• Dysphagia assessment: Videofluoroscopy/FEES if aspiration suspected
• Swallowing strategies, dietary modifications (thickened fluids, soft diet)
• Communication strategies if language impaired

Driving

• DVLA Notification: Legal requirement to inform DVLA of dementia diagnosis
• Driving Assessment: OT driving assessment; many patients with early dementia can continue driving if safe
• Cease driving: If significant cognitive impairment, unsafe on assessment

Legal and Capacity Issues

• Mental Capacity Act Assessment: Assess capacity for specific decisions (financial, medical, residence)
• Lasting Power of Attorney (LPA): Encourage early (while patient has capacity to appoint)
  • LPA for Health and Welfare
  • LPA for Property and Financial Affairs
• Advance Decisions/Directives: Document wishes regarding resuscitation, invasive treatment, place of care
• Deprivation of Liberty Safeguards (DoLS): If care home placement restricts freedom

Carer Support (Essential)

• Education: Understanding dementia, behavioural management, practical care skills
• Respite Care: Day centres, respite admissions to relieve carer burden
• Support Groups: Alzheimer's Society, local carer groups
• Financial Support: Attendance Allowance, Carer's Allowance, Council Tax exemption
• Monitor Carer Health: Depression, burnout common; signpost to GP, counselling

---

9. Complications

---

10. Prognosis and Outcomes

Survival

• Median survival: 3-5 years from diagnosis [7]
• Prognosis worse than Alzheimer's disease: Due to high burden of cardiovascular comorbidity and increased cardiovascular mortality
• Predictors of Poor Prognosis:
  • Older age at diagnosis
  • Severe cognitive impairment at presentation
  • High burden of cerebrovascular lesions on imaging
  • Multiple cardiovascular comorbidities (heart failure, AF, CKD)
  • Gait disturbance and falls
  • Male sex

Progression

• Variable: Some patients remain stable for years if no further vascular events occur; others decline rapidly
• Stepwise vs Gradual: Multi-infarct dementia shows stepwise decline; subcortical disease shows gradual decline
• Predictors of Rapid Progression:
  • Recurrent strokes/TIAs
  • Uncontrolled vascular risk factors
  • Severe white matter disease on MRI
  • Coexisting Alzheimer's pathology (mixed dementia)

Functional Decline

• Instrumental ADL affected first: Finances, medication management, cooking, driving
• Basic ADL affected in moderate-severe stages: Dressing, bathing, toileting, eating
• End-Stage: Total dependence, bedbound, non-verbal, dysphagia

Cause of Death

---

11. Prevention

Primary Prevention (Before Dementia Onset)

Modifiable risk factors in midlife and late-life:

Secondary Prevention (After Diagnosis)

• Prevent further vascular events: As per management section above
• Optimise coexisting conditions: Heart failure, AF, diabetes
• Monitor and treat complications: Infections, falls, malnutrition

---

12. Evidence and Guidelines

Key Guidelines

Landmark Studies

1. HYVET-COG (2008)

• Question: Does treating hypertension in patients > 80 years reduce dementia incidence?
• Design: RCT; indapamide ± perindopril vs placebo
• Result: Non-significant trend towards reduced dementia (HR 0.86, 95% CI 0.67-1.09). Meta-analyses combining with other trials show significant benefit.
• Impact: Treat hypertension even in very elderly for cognitive protection [14]

2. GAL-INT-6 (Galantamine in Vascular Dementia)

• Question: Does galantamine improve cognition in vascular dementia?
• Design: RCT; galantamine vs placebo
• Result: Small improvement in cognitive scores but NO improvement in functional outcomes; increased adverse effects
• Impact: Led to NICE recommendation against routine use of AChE inhibitors in VaD [6]

3. PROGRESS (Perindopril Protection Against Recurrent Stroke Study)

• Question: Does blood pressure lowering prevent recurrent stroke and cognitive decline?
• Design: RCT; perindopril ± indapamide vs placebo in stroke/TIA patients
• Result: 28% reduction in recurrent stroke; significant reduction in cognitive decline
• Impact: Supports aggressive BP control post-stroke for cognitive protection [14]

4. SPRINT MIND (2019)

• Question: Does intensive BP control (less than 120 mmHg systolic) reduce dementia vs standard control (less than 140 mmHg)?
• Design: RCT in non-diabetic patients at high cardiovascular risk
• Result: Intensive control reduced MCI (HR 0.81, p=0.01); trend towards reduced dementia (HR 0.83, p=0.10)
• Impact: Supports aggressive BP targets for cognitive protection (though balance against falls risk in frail elderly) [14]

---

13. Examination Focus

Common Exam Scenarios

1. MRCP PACES / Clinical Examination

Station: Elderly patient with cognitive impairment and gait disturbance

Candidate Task: Perform cognitive assessment and neurological examination.

Key Findings:

• MoCA 19/30 (executive, attention, visuospatial impaired; memory relatively preserved with cues)
• Shuffling, broad-based gait; start hesitation
• Brisk reflexes, extensor plantars bilaterally
• Spastic dysarthria, emotional lability
• Irregularly irregular pulse (AF)

Diagnosis: Vascular dementia (subcortical ischaemic type) with pseudobulbar palsy

Discussion Points:

• Differential from Alzheimer's: Executive > memory; early gait; UMN signs; stepwise history
• Imaging: Request MRI brain (white matter hyperintensities, lacunes)
• Vascular risk factors: Hypertension, AF, smoking
• Management: Anticoagulation (AF), antihypertensive, statin, lifestyle; NOT AChE inhibitors
• Prognosis: Variable; prevent further strokes

2. MCQ/SBA Question

Question: A 72-year-old man with hypertension and type 2 diabetes presents with 2-year history of progressive cognitive decline. His wife reports he is slow in thinking, has difficulty planning activities, and has had two episodes of sudden worsening followed by partial improvement. He has a shuffling gait and early urinary incontinence. MMSE 24/30. What is the MOST appropriate initial pharmacological management?

A) Donepezil
B) Memantine
C) Antihypertensive optimisation and antiplatelet therapy
D) Quetiapine
E) Fluoxetine

Answer: C) Antihypertensive optimisation and antiplatelet therapy

Explanation: Clinical features (executive dysfunction, stepwise decline, gait disturbance, early incontinence) suggest vascular dementia. Vascular risk factor control (BP, antiplatelet, statin, diabetes control) is the ONLY evidence-based treatment. AChE inhibitors (donepezil) and memantine are NOT recommended for pure VaD per NICE guidelines.

3. Viva Voce Question

Examiner: "What are the key differences between vascular dementia and Alzheimer's disease?"

Model Answer:

4. Data Interpretation: MRI Report

Scenario: 68-year-old woman with 18-month cognitive decline. MRI brain report: "Extensive confluent periventricular and deep white matter T2/FLAIR hyperintensities (Fazekas grade 3). Multiple lacunar infarcts in bilateral basal ganglia and thalami. Cerebral microbleeds in deep locations. Mild generalised atrophy."

Question: Interpret the findings and implications for diagnosis and management.

Answer:

• Interpretation: Severe cerebral small vessel disease (subcortical ischaemic vascular dementia, Binswanger's type)
• Fazekas 3: Confluent white matter disease
• Lacunar infarcts + microbleeds: Markers of hypertensive arteriopathy
• Diagnosis: Vascular dementia (small vessel subtype) highly likely
• Management:
  • "Aggressive vascular risk factor control: BP target less than 140/90, statin, antiplatelet (clopidogrel)"
  • Assess for AF (Holter if needed); anticoagulate if present
  • "Caution with antihypertensives: Microbleeds indicate bleeding risk; balance stroke prevention vs bleeding risk"
  • Do NOT offer AChE inhibitors (per NICE)
  • "Multidisciplinary support: OT, PT (gait/falls), SALT (if dysphagia)"

---

Viva Examination Talking Points

1. Binswanger's Disease

• Eponym for subcortical ischaemic vascular dementia due to chronic small vessel disease
• Named after Otto Binswanger (Swiss psychiatrist, 1894)
• Characterised by extensive white matter disease (leukoaraiosis), lacunar infarcts, gradual cognitive decline
• Presents with subcortical features: executive dysfunction, bradyphrenia, gait disturbance, pseudobulbar palsy, early bladder symptoms
• Modern term: Subcortical ischaemic vascular dementia (SIVD)

2. NINDS-AIREN Criteria

• National Institute of Neurological Disorders and Stroke – Association Internationale pour la Recherche et l'Enseignement en Neurosciences
• Published 1993; most widely used research diagnostic criteria for vascular dementia
• Requires: (1) Dementia, (2) Cerebrovascular disease (clinical + imaging), (3) Temporal relationship
• Distinguishes probable vs possible vascular dementia
• Limitation: High specificity but low sensitivity (misses subcortical cases with gradual onset)

3. Pseudobulbar Palsy vs Bulbar Palsy

4. Hachinski Ischaemic Score

• Clinical scoring system (1975) to differentiate vascular dementia from Alzheimer's
• Scores clinical features (abrupt onset, stepwise, focal signs, hypertension, etc.)
• Score ≥7 suggests vascular; ≤4 suggests Alzheimer's
• Limitation: Largely historical; modern neuroimaging (MRI) is superior
• Value: Highlights clinical features distinguishing VaD from AD

5. CADASIL

• Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy
• Genetic small vessel disease; NOTCH3 gene mutation (chromosome 19)
• Presentation: Recurrent strokes/TIAs (30s-50s), migraine with aura, mood disturbance, progressive cognitive decline (vascular dementia)
• Imaging: Extensive white matter hyperintensities (anterior temporal lobes characteristic), lacunar infarcts, microbleeds
• Diagnosis: Genetic testing (NOTCH3 sequencing); skin biopsy (granular osmiophilic material in vascular smooth muscle)
• Treatment: Supportive; vascular risk factor control; no specific therapy

---

14. Patient and Layperson Explanation

What is Vascular Dementia?

Vascular dementia is a decline in memory and thinking skills caused by reduced blood flow to the brain. The brain needs a constant supply of oxygen and nutrients delivered by blood. When blood vessels in the brain are damaged—by strokes, narrowing of small vessels, or long-term conditions like high blood pressure—parts of the brain don't get enough blood and are damaged. This damage affects how the brain works, leading to problems with thinking, memory, and daily activities.

It is the second most common type of dementia after Alzheimer's disease, and accounts for about 1 in 5 dementia cases. In many older people, vascular dementia and Alzheimer's disease occur together (called "mixed dementia").

What Causes It?

Vascular dementia is caused by damage to blood vessels in the brain. This can happen in several ways:

1. Multiple small strokes (multi-infarct dementia): A series of small strokes, sometimes so mild you don't notice them at the time, gradually damage the brain.
2. Small vessel disease (Binswanger's disease): The tiny blood vessels deep in the brain become narrowed and hardened, reducing blood flow to important areas. This is the most common type.
3. A single large stroke: Sometimes one stroke in a critical part of the brain can cause dementia.
4. Narrowed or blocked blood vessels: Conditions like high blood pressure, diabetes, and high cholesterol damage blood vessels over time.

How is it Different from Alzheimer's Disease?

What are the Symptoms?

Symptoms depend on which part of the brain is damaged, but common features include:

• Slow thinking: Taking longer to process information, make decisions, or solve problems
• Difficulty planning and organising: Struggles with tasks that need multiple steps, like cooking a meal or managing finances
• Memory problems: Difficulty remembering recent events, though this is often milder than in Alzheimer's (cues and reminders help more)
• Confusion: Getting lost, forgetting the day or time
• Walking and balance problems: Shuffling gait, unsteadiness, falls
• Bladder problems: Needing to urinate urgently or frequently; incontinence
• Mood changes: Depression, apathy (loss of interest), emotional outbursts
• Difficulty speaking or swallowing (in advanced cases)

Can it be Treated?

Unfortunately, damage to the brain from strokes or poor blood flow cannot be reversed—dead brain cells do not grow back. However, we can stop vascular dementia from getting worse by preventing further damage.

The main treatment is protecting the brain from future strokes by:

1. Controlling blood pressure: High blood pressure is the biggest risk factor. Blood pressure tablets reduce the risk of further strokes.
2. Taking blood-thinning medicines: Aspirin or clopidogrel (or stronger blood thinners if you have an irregular heartbeat called atrial fibrillation) reduce stroke risk.
3. Lowering cholesterol: Statins protect blood vessels and reduce stroke risk.
4. Managing diabetes: Keeping blood sugar controlled prevents further blood vessel damage.
5. Stopping smoking: Smoking damages blood vessels; stopping reduces stroke risk significantly.
6. Healthy lifestyle: Regular exercise, healthy diet (Mediterranean-style), limiting alcohol.

What about dementia tablets? The medicines used for Alzheimer's disease (like donepezil) do not work well for pure vascular dementia and are not usually recommended. They may be considered if doctors think you have a mixture of Alzheimer's and vascular dementia.

What is the Outlook?

The outlook varies widely. Some people remain stable for years if no further strokes occur. Others may decline more rapidly, especially if they have ongoing vascular problems (uncontrolled high blood pressure, further strokes, heart disease).

On average, people with vascular dementia live 3-5 years after diagnosis, though this varies greatly. The most important thing you can do is control vascular risk factors to slow or halt progression.

Support and Resources

• Alzheimer's Society: Information, support groups, helpline (0333 150 3456)
• Age UK: Practical support, advice on benefits, care
• NHS Services: Memory clinic, GP, community nurses, occupational therapy, physiotherapy
• Legal Planning: Consider Lasting Power of Attorney, advance care planning while you have capacity to make decisions

---

15. References

Primary Sources

1. Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844-866. doi:10.1016/j.neuron.2013.10.008. PMID: 24267647.

2. Kalaria RN, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7(9):812-826. doi:10.1016/S1474-4422(08)70169-8. PMID: 18667359.

3. O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698-1706. doi:10.1016/S0140-6736(15)00463-8. PMID: 26590476.

4. Wardlaw JM, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838. doi:10.1016/S1474-4422(13)70124-8. PMID: 23867200.

5. Gorelick PB, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713. doi:10.1161/STR.0b013e3182299496. PMID: 21778438.

6. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers (NG97). NICE; 2018. Available at: https://www.nice.org.uk/guidance/ng97

7. Aguero-Torres H, et al. Prognostic factors in very old demented adults: a seven-year follow-up from a population-based survey in Stockholm. J Am Geriatr Soc. 1998;46(4):444-449. PMID: 9560065.

8. Reed BR, et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain. 2007;130(Pt 3):731-739. doi:10.1093/brain/awl385. PMID: 17267522.

9. Rosano C, et al. Subclinical brain magnetic resonance imaging abnormalities predict physical functional decline in high-functioning older adults. J Am Geriatr Soc. 2005;53(4):649-654. doi:10.1111/j.1532-5415.2005.53214.x. PMID: 15817012.

10. Parvizi J, et al. Pathological laughter and crying: a link to the cerebellum. Brain. 2001;124(Pt 9):1708-1719. doi:10.1093/brain/124.9.1708. PMID: 11522574.

11. Nasreddine ZS, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x. PMID: 15817019.

12. Chabriat H, et al. CADASIL. Lancet Neurol. 2009;8(7):643-653. doi:10.1016/S1474-4422(09)70127-9. PMID: 19539236.

13. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8(11):1006-1018. doi:10.1016/S1474-4422(09)70236-4. PMID: 19782001.

14. Peters R, et al. Hypertension and dementia: Pathophysiology and potential utility of antihypertensive treatment. Eur J Pharmacol. 2024;963:176252. doi:10.1016/j.ejphar.2023.176252. PMID: 38052309.

15. Kalantarian S, et al. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med. 2013;158(5 Pt 1):338-346. doi:10.7326/0003-4819-158-5-201303050-00007. PMID: 23460057.

16. O'Lone E, et al. Cognition in people with end-stage kidney disease treated with hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67(6):925-935. doi:10.1053/j.ajkd.2015.12.028. PMID: 26919914.

17. Walker KA, et al. Association between an inflammatory biomarker score and future dementia diagnosis in a large community-based cohort. Neurology. 2023;101(6):e613-e621. doi:10.1212/WNL.0000000000207481. PMID: 37467176.

18. Alexopoulos GS, et al. Depression in the elderly. Lancet. 2005;365(9475):1961-1970. doi:10.1016/S0140-6736(05)66665-2. PMID: 15936426.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions should always account for individual patient circumstances, local guidelines, and specialist consultation where appropriate. Always seek advice from qualified healthcare professionals.